title: Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
abstract: OBJECTIVE
  The aims of this study were to report the clinical outcomes of adjuvant chemo-radiotherapy after curative resection in 637 patients with gastric cancer.
  
  
  METHODS
  The retrospective analysis included 637 patients with resectable gastric cancer and stage IB-IV (M0) from 8 medical centers between 2003 and 2010. The patients were treated with 5FU-leucovorin and radiotherapy according to Schema for INT-0116.
  
  
  RESULTS
  Of the 637 patients, the median of overall survival (OS) was 43.7 months and relapse free survival (RFS) was 36.6 months. OS rates were 84%, 45%, 40% while RFS rates were 81%, 45% and 35% at 1, 3 and 5-years, respectively. Hematological and gastrointestinal toxicities (grade 1-4) were observed in 35% and 36.5% of patients, respectively. In univariate analysis, according to the Lauren classification, tumor grade, T stage, N stage, type of operation (total gastrectomy or subtotal) and surgery resection margin (R0 or R1) were found as prognostic factors on RFS and OS (p<0.05). In multivariate analysis, T stage, N stage and surgical margins were found as effective factors on OS. T stage, N stage and Lauren classification were factors affecting RFS.
  
  
  CONCLUSIONS
  Adjuvant chemo-radiotherapy after curative resection of gastric cancer was feasible, with acceptable toxicities in the Turkish population.
authors.affiliation: Anatolian Society of Medical Oncology Association (ASMO), Turkey. drmehmetonko@hotmail.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kucukoner
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Isikdogan
authors.forename: Erkan
authors.initials: E
authors.lastname: Arpaci
authors.forename: Mehmet
authors.initials: M
authors.lastname: Bilici
authors.forename: Dogan
authors.initials: D
authors.lastname: Uncu
authors.forename: Bulent
authors.initials: B
authors.lastname: Cetin
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.forename: Mevlude
authors.initials: M
authors.lastname: Inane
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Kaplan
authors.forename: Kerim
authors.initials: K
authors.lastname: Cayir
authors.forename: Tarkan
authors.initials: T
authors.lastname: Yetisyigit
authors.forename: Nuriye
authors.initials: N
authors.lastname: Ozdemir
authors.forename: Ali
authors.initials: A
authors.lastname: Inal
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.forename: Necati
authors.initials: N
authors.lastname: Alkis
authors.forename: Salim Basol
authors.initials: SB
authors.lastname: Tekin
authors.forename: Celalettin
authors.initials: C
authors.lastname: Eroglu
authors.forename: Serdar
authors.initials: S
authors.lastname: Turhal
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects / Q000401:mortality; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey; D055815:Young Adult
chemical_list: D002955:Leucovorin; D005472:Fluorouracil